Highlights and Quick Summary
- Depreciation & Amortization Growth for the quarter ending September 29, 2019 was 15.63% (a 17.34% increase compared to previous quarter)
- Year-over-year quarterly Depreciation & Amortization Growth decreased by -20.98%
- Annual Depreciation & Amortization Growth for 2018 was 17.59% (a -32.96% decrease from previous year)
- Annual Depreciation & Amortization Growth for 2017 was 26.24% (a -37.85% decrease from previous year)
- Annual Depreciation & Amortization Growth for 2016 was 42.22% (a 563.84% increase from previous year)
- Twelve month Depreciation & Amortization Growth ending September 29, 2019 was 15.25% (a 1.4% increase compared to previous quarter)
- Twelve month trailing Depreciation & Amortization Growth decreased by -13.3% year-over-year
Trailing Depreciation & Amortization Growth for the last four month:
| 29 Sep '19 | 29 Jun '19 | 30 Mar '19 | 30 Dec '18 |
|---|---|---|---|
| 15.25% | 15.04% | 15.97% | 17.59% |
Visit stockrow.com/ABBV
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Depreciation & Amortization Growth of AbbVie Inc.
Most recent Depreciation & Amortization Growthof ABBV including historical data for past 10 years.Interactive Chart of Depreciation & Amortization Growth of AbbVie Inc.
AbbVie Inc. Depreciation & Amortization Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2019 | – | 15.63% | 13.32% | 13.03% | – |
| 2018 | 19.78% | 14.78% | 16.89% | 18.98% | 17.59% |
| 2017 | 12.5% | 24.67% | 31.14% | 39.55% | 26.24% |
| 2016 | 25.67% | 33.92% | 52.11% | 69.62% | 42.22% |
| 2015 | 35.23% | 18.23% | -5.94% | -20.6% | 6.36% |
| 2014 | -3.5% | -17.95% | -14.41% | -12.33% | -12.37% |
| 2013 | -35.28% | 3.08% | -20.0% | -28.84% | -22.0% |
| 2012 | -4.89% | -27.99% | -7.12% | 1.44% | -9.59% |
| 2011 | – | – | -72.57% | -54.8% | 7.43% |
| 2010 | – | – | – | – | 69.75% |
Business Profile of AbbVie Inc.
Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. It offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, it offers AndroGel, a testosterone replacement therapy; CREON, a pancreatic enzyme therapy; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide molecule gonadotropin-releasing hormone antagonist. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; Calico Life Sciences LLC; Cystic Fibrosis Foundation; Dragonfly Therapeutics, Inc.; and Pan-Canadian Pharmaceutical Alliance. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.